Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

heart-lung machine, ECMO, levosimendan, heart failure drug, cardiovascular surgery outcomes, ACC.17 study
News | Pharmaceuticals | March 28, 2017

March 28, 2017 — When used as a preventive measure during heart surgery, the heart failure...

ECRI Institute, top 10 patient safety concerns, 2017 report, information technology, healthcare
News | Information Technology | March 24, 2017

March 24, 2017 — Safe implementation of...

bleeding complications, rivaroxaban, antiplatelet therapy, post-ACS, acute coronary syndrome, ACC.17 study
News | Antiplatelet and Anticoagulation Therapies | March 23, 2017

March 23, 2017 — Bleeding complications did not increase for patients with acute coronary syndrome treated with...

rivaroxaban, asprin, venous thromboembolism, VTE recurrence, clinical study, ACC.17
News | Antiplatelet and Anticoagulation Therapies | March 23, 2017

March 23, 2017 — In patients at elevated risk for a recurrence of potentially life- threatening blood clots, a low...

PCSK9 inhibitors, bococizumab, ACC .17, clinical trials, LDL cholesterol
News | Pharmaceuticals | March 22, 2017

March 22, 2017 — In a clinical program that was terminated early, the experimental PCSK9 inhibitor bococizumab, when...

RESOLVE study, RESOLVE trial, subclinical leaflet thrombosis

A CT study from the RESOLVE Trial showing valve leaflet thrombosis on a TAVR device. The trial examined a range of surgical and transcatheter valves to show thrombosis is found across both types of devices. It also examined if anticoagulation or antiplatelet therapy could reduce thrombosis and allow a greater range of leaflet motion.

Feature | Heart Valve Technology | March 21, 2017

March 21, 2017 — About 12 percent of patients undergoing aortic valve replacement developed non-symptomatic blood...

Evolocumab, Repatha, LDL, ACC late breaker, best LDL lowering drug
Feature | Pharmaceuticals | March 20, 2017

March 20, 2017 — The most important late-breaking pharmaceutical trial at the 2017 America College of Cardiology...

warfarin, anticoagulation therapy, atrial fibrillation patients, Duke Clinical Research Institute study, stroke
News | Antiplatelet and Anticoagulation Therapies | March 14, 2017

March 14, 2017 — More than 80 percent of stroke patients with a history of...

CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017

March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc. first-in-class Cobra...

ACC, Haymarket Medical Education, HME, myCME, RightSTEPS initiative, prescribing behavior, chronic heart failure
News | Heart Failure | February 22, 2017

February 22, 2017 — The American College of Cardiology (ACC), Haymarket Medical Education (HME) and myCME have...

Xarelto, rivaroxaban, COMPASS study, ends early,
News | Antiplatelet and Anticoagulation Therapies | February 09, 2017

February 9, 2017 — Janssen Research & Development LLC (Janssen) announced that the Phase 3 COMPASS trial is...

GE Healthcare, Rapiscan stress imaging agent, North America, Rapidscan Pharma Solutions Inc.
News | Pharmaceuticals | February 07, 2017

February 7, 2017 — GE Healthcare’s Life Sciences business announced in January that it acquired Rapidscan Pharma...

Overlay Init